Reply - 31/07/13
Doi : 10.1016/j.jaci.2013.04.041
Hugh A. Sampson, MD a 
, Roy Gerth van Wijk, MD b, Carsten Bindslev-Jensen, MD, PhD c, Scott H. Sicherer, MD a, Suzanne Teuber, MD d, Wesley Burks, MD e, Anthoney E. Dubois, MD f, Kirsten Beyer, MD g, Philippe A. Eigenmann, MD h, Jonathan M. Spergel, MD, PhD i, Thomas Werfel, MD j
, Roy Gerth van Wijk, MD b, Carsten Bindslev-Jensen, MD, PhD c, Scott H. Sicherer, MD a, Suzanne Teuber, MD d, Wesley Burks, MD e, Anthoney E. Dubois, MD f, Kirsten Beyer, MD g, Philippe A. Eigenmann, MD h, Jonathan M. Spergel, MD, PhD i, Thomas Werfel, MD j a Mount Sinai School of Medicine, New York, New York
b Erasmus Medical Center, Rotterdam, The Netherlands
c Odense University Hospital, Odense, Denmark
d University of California-Davis School of Medicine, Davis, Calif
e University of North Carolina School of Medicine, Chapel Hill, NC
f University of Groningen, University Medical Center Groningen, Department of Pediatric Pulmonology and Pediatric Allergy, and the GRIAC Research Institute, Groningen, The Netherlands
g Charité University Hospital, Clinic for Pediatric Pneumology and Immunology, Berlin, Germany
h Children’s University Hospital of Geneva, Geneva, Switzerland
i Children’s Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa
j Hannover Medical School, Hannover, Germany
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: H. A. Sampson has received consultancy fees from Allertein Therapeutics; is employed by the Icahn School of Medicine at Mount Sinai; has received research support from the National Institute of Allergy and Infectious Disease (NIAID), the Food Allergy Initiative, and the Thermo Fisher Scientific; and receives royalties from UpToDate and Elsevier. R. G. van Wijk has received consultancy fees from MSD, HAL, and Crucell; has received research support from NWO, STW, Novartis, Biomay, and DBV; has received lecture fees from Allergopharma; has received payment for manuscript preparation from Chiesi; and receives royalties from de Tijdstroom and Bohn, Stafleu, van Loghum. C. Bindslev-Jensen has received travel support from the European Academy of Allergology and Clinical Immunology (EAACI); and has received lecture fees from MSD and Thermo Fisher Scientific. S. H. Sicherer has received consultancy fees from the Food Allergy Initiative. S. Teuber has received consultancy fees from Sanofi-Aventis and the International Food Information Council and has received lecture fees from the Kaiser Permanente Foundation and California Society of Allergy, Asthma & Immunology. W. Burks has received research support from the National Institutes of Health (NIH); was on the American Academy of Allergy, Asthma & Immunology (AAAAI) Board; was a member of the NIH Study Section (HAI); was on the US Food and Drug Administration (FDA) Food Advisory Committee; was on the Merck US Allergy Immunotherapy Allergist Advisory Board; is on the Food Allergy & Anaphylaxis Network Research Advisory Board; has received consultancy fees from ActoGeniX, Dow AgroSciences, McNeill Nutritionals, Merck, Novartis, Sanofi-Aventis, Schering Plough, and Unilever; was employed by Duke University and is employed by UNC Children's Hospital; has received research support from the NIH and Wallace Research Foundation; has received lecture fees from Abbott Laboratories and Mylan Specialty; owns multiple patents; has received payment for developing educational presentations from Current Views 2012; and is a minority stockholder in Allertein and Mastcell Pharmaceuticals. A. E. Dubois has received travel support from the EAACI/AAAAI; is on the ALK-Abelló ABU advisory board; has received research support from ALK-Abelló ABU EAI research and Thermo Fisher Scientific; has received payment for the development of educational presentations from Mead Johnson; and has received travel support as a speaker from the EAACI and FAAM, PAAM. K. Beyer has received research support from the European Union German Research Foundation, the Foundation for the Treatment of Peanut Allergy, and Danone; has received consultancy fees from Danone, Novartis, ALK-Abelló, and Meda Pharma; and has received lecture fees from Danone, Phadia, InfectoPharm, CSL Behring, Novartis, UCB, Meda Pharma, Med Update, Allergopharma, and Thermo Fisher Scientific. P. A. Eigenmann has received travel support from the EAACI; has received consultancy fees from DBV Technologies, Danone, Nestlé, and ALK-Abelló; has received research support from LETI and Nestlé; has received lecture fees from Stallergenes, Sodilac, and Phadia; has received royalties from UpToDate and Elsevier; and has stock/stock options in DBV Technologies. J. M. Spergel is on the DBV Board; has received research support from Nutricia and the Department of Defense; has received lecture fees from MEI and Nutricia; receives royalties from UpToDate; has received payment for the development of educational presentations from MEI; and has stock/stock options in DBV. T. Werfel declares he has no relevant conflicts of interest. |
© 2013
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 132 - N° 2
P. 502-503 - août 2013 Retour au numéro
Article précédent
- Double-blind food challenges can be conducted effectively by using interspersed active and placebo doses among children
- Tom Marrs, George du Toit, Adam T. Fox, Michael R. Perkin, Gideon Lack
- Eosinophilic esophagitis treated with immunotherapy to dust mites
- Robert M. Ramirez, Robert L. Jacobs
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?